yahoo_financeOriginal article
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
Phase 1positiveRT-114Positive
AI Analysis
Summary
Rani Therapeutics announced positive Phase 1a data for RT-114, an oral obesity treatment candidate that demonstrated oral bioavailability exceeding matched subcutaneous dosing.
Clinical Trial Data
Phase
1a
Primary Endpoint
Met
Outcome Details
Oral bioavailability exceeding matched subcutaneous dosing
Importance:6/10
Sentiment:
0.75
obesityoral deliveryphase 1apositive databioavailability
Related Companies
Read the original article
Published by yahoo_finance on July 15, 2026 12:00 PM